Acquisition Momentum Target companies and CROs in autoimmune and rare disease spaces should be engaged given Selecta’s recent acquisition of Cartesian Therapeutics and related financing, signaling a growth trajectory and a broadened pipeline.

Immunology Platform Leverage Selecta’s SVP™ immune tolerance platform and ImmTOR approach to position complementary collaboration opportunities with partners seeking targeted immune modulation for autoimmune conditions, vaccine delivery, or tolerance induction.

Clinical-stage Partnering Prioritize discussions with pharma and biotech players seeking late-stage or clinical-stage immunotherapies to co-develop or license programs, leveraging Selecta’s niche focus on targeted immunotherapies and rare diseases.

Funding & Growth Highlight the recent $60M private financing and merger activity as proof of investor confidence, using it to validate potential joint ventures, strategic collaborations, and accelerated programs to attract co-development or funding partners.

Operational Scale Although the company is 11-50 employees, align outreach around scalable collaboration models, including licensing, milestone-based deals, and CRO-focused partnerships that can accelerate development without large internal headcount expansion.